| The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms R Alaggio, C Amador, I Anagnostopoulos, AD Attygalle, IBO Araujo, ... Leukemia 36 (7), 1720-1748, 2022 | 2680 | 2022 |
| Nonbiopsy diagnosis of cardiac transthyretin amyloidosis JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy, A Dispenzieri, ... Circulation 133 (24), 2404-2412, 2016 | 1968 | 2016 |
| Systemic amyloidosis AD Wechalekar, JD Gillmore, PN Hawkins The Lancet 387 (10038), 2641-2654, 2016 | 1092 | 2016 |
| New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes G Palladini, A Dispenzieri, MA Gertz, S Kumar, A Wechalekar, ... Journal of clinical oncology 30 (36), 4541-4549, 2012 | 1021 | 2012 |
| Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis M Fontana, S Pica, P Reant, A Abdel-Gadir, TA Treibel, SM Banypersad, ... Circulation 132 (16), 1570-1579, 2015 | 627 | 2015 |
| The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group N Leung, F Bridoux, V Batuman, A Chaidos, P Cockwell, VD D’Agati, ... Nature Reviews Nephrology 15 (1), 45-59, 2019 | 558 | 2019 |
| A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis AD Wechalekar, SO Schonland, E Kastritis, JD Gillmore, MA Dimopoulos, ... Blood, The Journal of the American Society of Hematology 121 (17), 3420-3427, 2013 | 549 | 2013 |
| Daratumumab-based treatment for immunoglobulin light-chain amyloidosis E Kastritis, G Palladini, MC Minnema, AD Wechalekar, A Jaccard, HC Lee, ... New England Journal of Medicine 385 (1), 46-58, 2021 | 506 | 2021 |
| Native T1 mapping in transthyretin amyloidosis M Fontana, SM Banypersad, TA Treibel, V Maestrini, DM Sado, SK White, ... JACC: Cardiovascular Imaging 7 (2), 157-165, 2014 | 476 | 2014 |
| Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis T Lane, M Fontana, A Martinez-Naharro, CC Quarta, CJ Whelan, A Petrie, ... Circulation 140 (1), 16-26, 2019 | 466 | 2019 |
| A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis G Palladini, S Sachchithanantham, P Milani, J Gillmore, A Foli, ... Blood, The Journal of the American Society of Hematology 126 (5), 612-615, 2015 | 461 | 2015 |
| Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis RL Comenzo, D Reece, G Palladini, D Seldin, V Sanchorawala, ... Leukemia 26 (11), 2317-2325, 2012 | 449 | 2012 |
| Senile systemic amyloidosis: clinical features at presentation and outcome JH Pinney, CJ Whelan, A Petrie, J Dungu, SM Banypersad, ... Journal of the American Heart Association 2 (2), e000098, 2013 | 440 | 2013 |
| T1 mapping and survival in systemic light-chain amyloidosis SM Banypersad, M Fontana, V Maestrini, DM Sado, G Captur, A Petrie, ... European heart journal 36 (4), 244-251, 2015 | 434 | 2015 |
| Systemic Amyloidosis in E ngland: an epidemiological study JH Pinney, CJ Smith, JB Taube, HJ Lachmann, CP Venner, SDJ Gibbs, ... British journal of haematology 161 (4), 525-532, 2013 | 380 | 2013 |
| Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis E Kastritis, AD Wechalekar, MA Dimopoulos, G Merlini, PN Hawkins, ... Journal of Clinical Oncology 28 (6), 1031-1037, 2010 | 362 | 2010 |
| CMR-based differentiation of AL and ATTR cardiac amyloidosis JN Dungu, O Valencia, JH Pinney, SDJ Gibbs, D Rowczenio, ... Jacc: cardiovascular imaging 7 (2), 133-142, 2014 | 357 | 2014 |
| Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study SM Banypersad, DM Sado, AS Flett, SDJ Gibbs, JH Pinney, V Maestrini, ... Circulation: Cardiovascular Imaging 6 (1), 34-39, 2013 | 351 | 2013 |
| Updates in cardiac amyloidosis: a review SM Banypersad, JC Moon, C Whelan, PN Hawkins, AD Wechalekar Journal of the American Heart Association 1 (2), e000364, 2012 | 350 | 2012 |
| Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival CP Venner, T Lane, D Foard, L Rannigan, SDJ Gibbs, JH Pinney, ... Blood, The Journal of the American Society of Hematology 119 (19), 4387-4390, 2012 | 349 | 2012 |
